Alpha Tau

Mr. Sofer specializes in medical devices development, regulation, reimbursement and marketing and has 20 years of experience in business across different industries including homeland security, manufacturing and trading. He held executive positions in public and private enterprises, including chairman, CEO, CFO and board member, and has wide experience with the capital market, IPOs, secondary offering and mergers and acquisitions.

The inventor of the technology. Prof. Kelson is a retired Chairman of the Tel Aviv University Physics Department. He has held research and teaching positions at the Weizmann Institute, Yale University, Lawrence Livermore National Laboratory, University of Wisconsin, Brookhaven National Laboratory, and other institutions.

Prof. Keisari is a member of the Human Microbiology Department, Tel Aviv University. His studies focus on in-situ destruction of solid metastatic tumors in order to stimulate anti-tumor immune reactivity and eradicate metastases. Professor Keisari teaches immunology and has held a variety of faculty management positions at the Faculty of Medicine of Tel Aviv University. He was a Postdoctoral Fellow at the Tumor Biology Department, National Cancer Institute of the NIH, Bethesda, USA.

Raphi joined Alpha Tau after 13 years in investment banking at Goldman Sachs in New York and in Tel Aviv. Most recently, he was Executive Director in charge of healthcare investment banking efforts in Goldman Sachs in Israel. Raphi obtained a BS degree in Economics from the Wharton School and BSE, MSE in Electrical Engineering from University of Pennsylvania.

Dr. Zelevsky is a board-certified radiation oncologist, the Chief of Brachytherapy and co-leader of the Genitourinary Disease Management Team at Memorial Sloan Kettering Cancer Center in New York. Dr. Zelefsky teaches both as an Associate Professor of Radiation Oncology at Memorial Sloan Kettering as well as Professor of Radiation Oncology at Weill Cornell Medical College, Cornell University, since 1994. He has been the Principal Investigator who tested C225 in conjunction with chemo-radiotherapy for advanced head and neck cancer.

Associate Professor of Radiation Oncology, Cancer Biology and Urology at Thomas Jefferson University, who specializes in radiation oncology and co-leads the Sidney Kimmel Cancer Center Multidisciplinary Genitourinary Clinic. Graduate of Yale University and Harvard Medical School.

Mr. Gat specializes in marketing strategy, branding, pricing and international sales management. He has over 15 years of experience in medical device and healthcare industries. He held managerial positions in public and private companies, including VP of marketing and sales, marketing strategy consultant and product manager, as well as serving as a senior paramedic in the Israeli national emergency services.